{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:52:05Z","timestamp":1774659125007,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00774-020-01190-2","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T20:11:52Z","timestamp":1609963912000},"page":"583-588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism"],"prefix":"10.1007","volume":"39","author":[{"given":"Midori","family":"Minezaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-1139","authenticated-orcid":false,"given":"Yuichi","family":"Takashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Mitsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yamao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadachika","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiji","family":"Kawanami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"Suppl 2","key":"1190_CR1","first-page":"N18","volume":"17","author":"S Adami","year":"2002","unstructured":"Adami S, Marcocci C, Gatti D (2002) Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 17(Suppl 2):N18-23","journal-title":"J Bone Miner Res"},{"key":"1190_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1359\/JBMR.050910","volume":"21","author":"RA Wermers","year":"2006","unstructured":"Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton LJ 3rd (2006) Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993\u20132001: an update on the changing epidemiology of the disease. J Bone Miner Res 21:171\u2013177","journal-title":"J Bone Miner Res"},{"key":"1190_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2265.2008.03520.x","volume":"71","author":"N Yu","year":"2009","unstructured":"Yu N, Donnan PT, Murphy MJ, Leese GP (2009) Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol (Oxf) 71:485\u2013493","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1190_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1210\/jc.2012-4022","volume":"98","author":"MW Yeh","year":"2013","unstructured":"Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, Haigh PI, Adams AL (2013) Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98:1122\u20131129","journal-title":"J Clin Endocrinol Metab"},{"key":"1190_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMcp1714213","volume":"379","author":"KL Insogna","year":"2018","unstructured":"Insogna KL (2018) Primary hyperparathyroidism. N Engl J Med 379:1050\u20131059","journal-title":"N Engl J Med"},{"key":"1190_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/00000658-200205000-00008","volume":"235","author":"R Udelsman","year":"2002","unstructured":"Udelsman R (2002) Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg 235:665\u2013670 (discussion 670-662)","journal-title":"Ann Surg"},{"key":"1190_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/00000658-199509000-00017","volume":"222","author":"AK Chan","year":"1995","unstructured":"Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH (1995) Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case\u2013control study. Ann Surg 222:402\u2013412 (discussion 412-404)","journal-title":"Ann Surg"},{"key":"1190_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1067\/msy.2000.110844","volume":"128","author":"GB Talpos","year":"2000","unstructured":"Talpos GB, Bone HG 3rd, Kleerekoper M, Phillips ER, Alam M, Honasoge M, Divine GW, Rao DS (2000) Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 128:1013\u20131020","journal-title":"Surgery"},{"key":"1190_CR9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/bmj.327.7414.530","volume":"327","author":"P Vestergaard","year":"2003","unstructured":"Vestergaard P, Mosekilde L (2003) Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 327:530\u2013534","journal-title":"BMJ"},{"key":"1190_CR10","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1210\/jc.2004-0028","volume":"89","author":"DS Rao","year":"2004","unstructured":"Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415\u20135422","journal-title":"J Clin Endocrinol Metab"},{"key":"1190_CR11","first-page":"49","volume":"11","author":"Aace Aaes Task Force on Primary Hyperparathyroidism","year":"2005","unstructured":"Aace Aaes Task Force on Primary Hyperparathyroidism (2005) The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract 11:49\u201354","journal-title":"Endocr Pract"},{"key":"1190_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00774-006-0687-y","volume":"24","author":"T Kawata","year":"2006","unstructured":"Kawata T, Imanishi Y, Kobayashi K, Onoda N, Okuno S, Takemoto Y, Komo T, Tahara H, Wada M, Nagano N, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y (2006) Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 24:300\u2013306","journal-title":"J Bone Miner Metab"},{"key":"1190_CR13","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1210\/jc.2009-1472","volume":"94","author":"M Peacock","year":"2009","unstructured":"Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D (2009) Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 94:4860\u20134867","journal-title":"J Clin Endocrinol Metab"},{"key":"1190_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/ndt\/gfn654","volume":"24","author":"M Meola","year":"2009","unstructured":"Meola M, Petrucci I, Barsotti G (2009) Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 24:982\u2013989","journal-title":"Nephrol Dial Transplant"},{"key":"1190_CR15","doi-asserted-by":"publisher","first-page":"c195","DOI":"10.1159\/000313035","volume":"115","author":"M Ichii","year":"2010","unstructured":"Ichii M, Ishimura E, Okuno S, Chou H, Kato Y, Tsuboniwa N, Nagasue K, Maekawa K, Yamakawa T, Inaba M, Nishizawa Y (2010) Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 115:c195-202","journal-title":"Nephron Clin Pract"},{"key":"1190_CR16","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2215\/CJN.02110310","volume":"5","author":"H Komaba","year":"2010","unstructured":"Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, Nishioka M, Hasegawa H, Kurosawa T, Fukagawa M (2010) Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 5:2305\u20132314","journal-title":"Clin J Am Soc Nephrol"},{"key":"1190_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.pharmthera.2005.06.019","volume":"109","author":"N Nagano","year":"2006","unstructured":"Nagano N (2006) Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 109:339\u2013365","journal-title":"Pharmacol Ther"},{"key":"1190_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/jclinpath-2011-200100","volume":"64","author":"K Sumida","year":"2011","unstructured":"Sumida K, Nakamura M, Ubara Y, Marui Y, Tanaka K, Takaichi K, Tomikawa S, Inoshita N, Ohashi K (2011) Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. J Clin Pathol 64:756\u2013760","journal-title":"J Clin Pathol"},{"key":"1190_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627\u2013635","journal-title":"J Pharmacol Exp Ther"},{"key":"1190_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","volume":"67","author":"M Colloton","year":"2005","unstructured":"Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467\u2013476","journal-title":"Kidney Int"},{"key":"1190_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00223-011-9490-4","volume":"89","author":"Y Imanishi","year":"2011","unstructured":"Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M (2011) Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. Calcif Tissue Int 89:29\u201335","journal-title":"Calcif Tissue Int"},{"key":"1190_CR22","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000357951","volume":"124","author":"R Tatsumi","year":"2013","unstructured":"Tatsumi R, Komaba H, Kanai G, Miyakogawa T, Sawada K, Kakuta T, Fukagawa M (2013) Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses. Nephron Clin Pract 124:224\u2013231","journal-title":"Nephron Clin Pract"},{"key":"1190_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/SLA.0b013e31824c5252","volume":"255","author":"XM Keutgen","year":"2012","unstructured":"Keutgen XM, Buitrago D, Filicori F, Kundel A, Elemento O, Fahey TJ 3rd, Zarnegar R (2012) Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database. Ann Surg 255:981\u2013985","journal-title":"Ann Surg"},{"key":"1190_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","volume":"98","author":"EF Nemeth","year":"2016","unstructured":"Nemeth EF, Goodman WG (2016) Calcimimetic and calcilytic drugs: feats, flops, and futures. Calcif Tissue Int 98:341\u2013358","journal-title":"Calcif Tissue Int"},{"key":"1190_CR25","first-page":"1054","volume":"85","author":"DS Rao","year":"2000","unstructured":"Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Parfitt AM (2000) Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 85:1054\u20131058","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01190-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01190-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01190-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T03:35:18Z","timestamp":1625715318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01190-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01190-2","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}